- Conditions
- Lymphoma, Large-Cell, Diffuse
- Interventions
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 16
- States / cities
- Sacramento, California • New Haven, Connecticut • Chicago, Illinois + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1369–1392
of 1,806
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Lymphoma
- Interventions
- SCRI-CAR22v2
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2040
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Houston, Texas + 1 more
- Conditions
- Lymphoma
- Interventions
- Parsaclisib, Hexal, Gazyvaro
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 6
- States / cities
- Gilbert, Arizona • La Jolla, California • Fairway, Kansas + 3 more
- Conditions
- CD19+ Acute Leukemia
- Interventions
- Patient Derived CD19 specific CAR T cells also expressing an EGFRt
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2036
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Oakland, California • Seattle, Washington
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma
- Interventions
- Navitoclax, Chemotherapy, Venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 12
- States / cities
- Duarte, California • Palo Alto, California • Chicago, Illinois + 9 more
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma
- Interventions
- Decitabine, Venetoclax, Calaspargase pegol-mknl
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
- Interventions
- DPX-Survivac, Pembrolizumab, CPA
- Drug
- Lead sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 17
- States / cities
- Fountain Valley, California • Boca Raton, Florida • Hollywood, Florida + 13 more
- Conditions
- B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat, Pharmacokinetic Study, Pharmacological Study
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Duarte, California • Buffalo, New York
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Iodine-131 Anti-B1 Antibody
- Drug
- Lead sponsor
- Corixa Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- South San Francisco, California
- Conditions
- Multiple Myeloma, Lymphoma, Non-Hodgkin's
- Interventions
- cemsidomide, Dexamethasone Oral
- Drug
- Lead sponsor
- C4 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more
- Conditions
- Lymphoma
- Interventions
- rituximab, pegylated liposomal doxorubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
- Interventions
- Sonrotoclax
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Fort Wayne, Indiana • New Orleans, Louisiana + 3 more
- Conditions
- B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL
- Interventions
- Blinatumomab, Haplo-Mismatched Cell Therapy (HMCT)
- Drug · Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Peripheral T-Cell Lymphoma
- Interventions
- Brentuximab vedotin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- T-Cell and NK-Cell Neoplasm
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- Duarte, California • Denver, Colorado • Tampa, Florida + 6 more
- Conditions
- Indolent Lymphoma
- Interventions
- Copanlisib, Nivolumab, Rituximab
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • Omaha, Nebraska + 1 more
- Conditions
- Solid Tumor, Lymphoma, Central Nervous System Tumors
- Interventions
- Durvalumab; MEDI4736
- Drug
- Lead sponsor
- Leo Mascarenhas
- Other
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Glofitamab, Obinutuzumab, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 11
- States / cities
- Duarte, California • Atlanta, Georgia • Lexington, Kentucky + 6 more
- Conditions
- Chronic Myeloproliferative Disorders, Diamond-blackfan Anemia, Fanconi Anemia, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, filgrastim, melphalan, methylprednisolone, mycophenolate mofetil, radiation therapy, umbilical cord blood transplantation
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 45 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 22
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 19 more
- Conditions
- Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegfilgrastim, Rituximab, Vincristine Sulfate
- Biological · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma, Interdigitating Dendritic Cell Sarcoma
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Omaha, Nebraska
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Methemoglobinemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
- Interventions
- chemotherapy, dapsone, medical chart review, assessment of therapy complications
- Drug · Other · Procedure
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
- Conditions
- Leukemia, Lymphoma
- Interventions
- sirolimus
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania